Arif Shakir, MD
Cardiovascular Disease · Midwest City, OKNPI 1326075789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,966 of the $7,271 with a category attached, or 82.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,069, 2.8 times the $750 reported in 2019.
Across 338 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Pfizer$795
- Johnson & Johnson$677
- Merck$653
- AstraZeneca$494
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,16916%
- Food & beverage$5,96682%
- Education$1362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $1,517 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 55 | $1,057 |
| Pfizer | 52 | $795 |
| Johnson & Johnson | 39 | $677 |
| Merck | 33 | $653 |
| AstraZeneca | 27 | $494 |
| Novartis | 27 | $380 |
| Esperion Therapeutics, Inc. | 14 | $229 |
| Amarin Pharma, Inc. | 16 | $223 |
| Lexicon Pharmaceuticals, Inc. | 10 | $192 |
| E.r. Squibb & Sons, L.L.C. | 7 | $183 |
| Novo Nordisk | 10 | $180 |
| Boehringer Ingelheim | 7 | $135 |
| Amgen | 5 | $93 |
| Boston Scientific | 4 | $87 |
| Kestra Medical Technology Services, Inc. | 3 | $59 |
| Abbott | 3 | $44 |
| Abiomed | 2 | $40 |
| Chiesi USA, Inc. | 1 | $38 |
| Edwards Lifesciences | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Biotronik Inc. | 1 | $17 |
| Recor Medical Inc | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Silk Road Medical, Inc. | 1 | $13 |
| Shockwave Medical, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,271 in reported general payments places this provider in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $219,847 |
| EntrestoSacubitril/Valsartan | 96 | $119,913 |
| BrilintaTicagrelor | 70 | $59,585 |
| FarxigaDapagliflozin Propanediol | 55 | $58,043 |
| OzempicSemaglutide | 21 | $28,348 |
| XareltoRivaroxaban | 19 | $26,918 |
| VerquvoVericiguat | 21 | $25,202 |
| JanuviaSitagliptin Phosphate | 14 | $20,727 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $16,990 |
| NexletolBempedoic Acid | 19 | $8,239 |
| Atorvastatin Calcium | 533 | $7,648 |
| Metoprolol Succinate | 507 | $7,154 |
| ClopidogrelClopidogrel Bisulfate | 584 | $6,998 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,432 |
| Nitroglycerin | 173 | $4,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $795 | $219,847187 claims |
| NovartisEntresto | $380 | $119,91396 claims |
| AstraZenecaBrilinta, Farxiga | $494 | $117,628125 claims |
| MerckVerquvo, Januvia | $653 | $45,92935 claims |
| Novo NordiskOzempic | $180 | $28,34821 claims |
| Johnson & JohnsonXarelto | $677 | $26,91819 claims |
| Esperion Therapeutics, Inc.Nexletol | $229 | $8,23919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Midwest City
- Asim ChohanMidwest City$19K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.